Moderna and Merck team up again, this time in oncology; Merck exercises option for mRNA-4157
Building on a successful partnership that began last year, Moderna Therapeutics LLC and Merck & Co. Inc. joined forces again, this time to develop mRNA-based personalized cancer vaccines that could be complementary to Merck's anti-PD-1 antibody therapy Keytruda.
- Antisense, Oligonucleotides
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.